Enhanced activity of AZD5582 and SM-164 in rabies virus glycoprotein-lactoferrin-liposomes to downregulate inhibitors of apoptosis proteins in glioblastoma.
Kuo YC, Lee YJ, Rajesh R.
Biomater Adv · journal article · DOI 10.1016/j.msec.2021.112615 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för SM-164. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
13 träffarThe IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice.
Lei W, Duan R, Li J, Liu X, Huston A, Boyce BF, Yao Z.
Sci Rep · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41598-020-64018-zSM‑164 enhances the antitumor activity of adriamycin in human U2‑OS cells via downregulation of X‑linked inhibitor of apoptosis protein.
Chen J, Chen X, Chen X, Sun H, Yang D.
Mol Med Rep · research-article; journal article · DOI 10.3892/mmr.2019.10181Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
Wu MS, Wang GF, Zhao ZQ, Liang Y, Wang HB, Wu MY, Min P, Chen LZ, Feng QS, Bei JX, Zeng YX, Yang D.
Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-13-0017Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells.
Zhang S, Li G, Zhao Y, Liu G, Wang Y, Ma X, Li D, Wu Y, Lu J.
PLoS One · comparative study; research-article; journal article · DOI 10.1371/journal.pone.0051461Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer.
Zhou B, Zhang J, Chen G, You L, Zhang TP, Zhao YP.
Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2012.10.039Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents.
Peng Y, Sun H, Lu J, Liu L, Cai Q, Shen R, Yang CY, Yi H, Wang S.
J Med Chem · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1021/jm201072xSmac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis.
Yang D, Zhao Y, Li AY, Wang S, Wang G, Sun Y.
Breast Cancer Res Treat · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s10549-011-1752-3Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity.
Sun H, Liu L, Lu J, Bai L, Li X, Nikolovska-Coleska Z, McEachern D, Yang CY, Qiu S, Yi H, Sun D, Wang S.
J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/jm101651bTherapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, Miller R, Liao J, Yi H, Liu M, Bellail A, Hao C, Sun SY, Ting AT, Wang S.
Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-10-0864Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.
Yang J, McEachern D, Li W, Davis MA, Li H, Morgan MA, Bai L, Sebolt JT, Sun H, Lawrence TS, Wang S, Sun Y.
Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-10-0643SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.
Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, Miller RS, Yi H, Shangary S, Sun Y, Meagher JL, Stuckey JA, Wang S.
Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/0008-5472.can-08-2655Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP.
Sun H, Nikolovska-Coleska Z, Lu J, Meagher JL, Yang CY, Qiu S, Tomita Y, Ueda Y, Jiang S, Krajewski K, Roller PP, Stuckey JA, Wang S.
J Am Chem Soc · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1021/ja074725f